PALI Projected Dividend Yield
Com Par $0.001/Palisade Bio Inc ( NASDAQ : PALI )Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). 21 YEAR PERFORMANCE RESULTS |
PALI Dividend History Detail PALI Dividend News PALI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |